camptothecin has been researched along with Melanoma in 60 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 3 (5.00) | 18.7374 |
| 1990's | 15 (25.00) | 18.2507 |
| 2000's | 24 (40.00) | 29.6817 |
| 2010's | 15 (25.00) | 24.3611 |
| 2020's | 3 (5.00) | 2.80 |
| Authors | Studies |
|---|---|
| Adamovics, JA; Hutchinson, CR | 1 |
| Acoca, S; Beauparlant, P; Bélec, L; Billot, X; Cluse, L; Goulet, D; Johnstone, RW; Marcellus, RC; Murthy Madiraju, SR; Nguyen, M; Purisima, E; Roulston, A; Serfass, L; Shore, GC; Viallet, J; Watson, M; Wiegmans, A | 1 |
| Ben-David, G; Firer, MA; Gancz, A; Gellerman, G; Gilad, Y; Luboshits, G; Minnes, R; Senderowitz, H; Tuchinsky, H | 1 |
| Kumar, RS; Nayaka, S; Rudrappa, M | 1 |
| Cao, S; Chen, X; Li, J; Li, Y; Lian, C; Peng, C; Su, J; Tao, J; Wu, L; Zeng, W; Zhao, S; Zhou, J | 1 |
| Li, S; Yu, Y; Zhang, F; Zhang, Q | 1 |
| Kim, HS; Lee, JJ; Park, IH; Rhee, WJ; Shin, JS | 1 |
| Aliberti, C; Bazzi, M; Campana, LG; Chiarion-Sileni, V; Midena, E; Parrozzani, R; Pigozzo, J; Pilati, P; Valpione, S | 1 |
| Berntzen, DT; Carling, U; Dorenberg, EJ; Dueland, S; Edwin, B; Eide, NA; Haugvik, SP; Røsok, B | 1 |
| Arifa, RDN; Barcelos, LS; Garcia, ZM; Krambrock, K; Ladeira, LO; Lima, RL; Madeira, MFM; Paula, TP; Pinheiro, MVB; Pinho, V; Souza, DG; Teixeira, MM; Ÿvila, TV | 1 |
| Chen, X; Kent, MS; Rodriguez, CO; Zhang, J | 1 |
| Bastien, S; Bicaku, E; Daud, AI; Dawson, J; DeConti, RC; Hausheer, FA; Lush, R; Marchion, D; Munster, PN; Neuger, A; Sullivan, DM | 1 |
| He, QJ; Lu, W; Luo, PH; Tu, CX; Wu, HH; Yang, B; Yang, XC; Zhou, XL; Zhu, DF; Zhu, H | 1 |
| Amschler, K; Erpenbeck, L; Pletz, N; Schön, M; Schön, MP; Wallbrecht, K | 1 |
| Aboody, KS; Chen, MY; Gutova, M; Kim, SU; Najbauer, J; Potter, PM | 1 |
| Cervinka, M; Rudolf, E; Rudolf, K | 2 |
| Berrevoet, F; Bocchetti, T; de Hemptinne, B; Ricciardi, S; Rogiers, X; Sainz-Barriga, M; Troisi, RI; Van Huysse, J; Vandenbossche, B; Vinci, A | 1 |
| Cichorek, M | 1 |
| Balivada, S; Basel, MT; Bossmann, SH; Myers, C; Pyle, M; Rachakatla, RS; Seo, GM; Shrestha, TB; Tamura, M; Troyer, DL; Wang, H | 1 |
| Daud, AI; Munster, PN | 1 |
| Agostini, G; Aldrighetti, L; Cappio, S; De Cobelli, F; Del Maschio, A; Losio, C; Orsi, M; Pilla, L; Ratti, F; Venturini, M | 1 |
| Aydiner, A; Camlica, H; Kurul, S; Tas, F; Topuz, E | 1 |
| Hao, C; Herlyn, M; Petruk, KC; Song, DK; Song, JH | 1 |
| Anichini, A; Bersani, I; Molla, A; Piris, A; Scarito, A; Vegetti, C; Zanon, M | 1 |
| Bergottini, R; De Cesare, M; Pratesi, G; Veneroni, S; Zunino, F | 1 |
| Berghorn, E; Centeno, B; Daud, A; Deconti, RC; Derderian, J; Hausheer, F; Liu, Z; Munster, P; Sullivan, D; Sullivan, P; Urbas, P; Valkov, N | 1 |
| Balsari, A; Carenini, N; De Cesare, M; Del Bufalo, D; Perego, P; Pratesi, G; Righetti, SC; Rivoltini, L; Zunino, F; Zupi, G | 1 |
| Duncan, J; McLeod, HL; Scheffer, GL; Scheper, RJ; Shannon, WD; Zhang, W | 1 |
| Alvarez-Silva, M; da Costa, R; de Faria, TJ; Dora, CL; Fernandes, D; Lemos-Senna, E; Stimamiglio, M; Trentin, AG | 1 |
| Bryl, E; Cichorek, M; Kozłowska, K | 1 |
| Eiseman, JL; Engbers, C; Joseph, E; Parise, RA; Strychor, S; Tonda, ME; Walsh, DR; Yu, NY; Zamboni, BA; Zamboni, WC | 1 |
| Gao, K; Lam, W; Li, G; Li, J; Lockwood, WW | 1 |
| Giovanella, BC; Kozielski, AJ; Mendoza, J; Potmesil, M; Stehlin, JS; Vardeman, D | 1 |
| Kraut, E; Muller, MT; Staubus, A; Subramanian, D; Young, DC | 1 |
| Bussey, AM; Ng, CE; Raaphorst, GP | 1 |
| Giovanella, B; Kozielski, A; Pantazis, P; Petry, E; Rodriguez, R; Wall, M; Wani, M | 1 |
| DeJesus, AR; Early, JA; Giovanella, BC; Mendoza, JT; Pantazis, P | 1 |
| Caserini, C; Orlandi, L; Silvestrini, R; Supino, R; Vaglini, M; Zaffaroni, N; Zunino, F | 1 |
| Boothman, DA; Kinsella, TJ; Lamond, JP; Wang, M | 2 |
| Balcerzak, SP; Gochnour, D; Kraut, EH; Staubus, A; Walker, MJ | 1 |
| Aoyagi, K; Aoyagi, Y; Asao, T; Okazaki, S; Sano, M; Utsugi, T; Wierzba, K; Yamada, Y | 1 |
| Ho, V; Li, G; Tang, L; Tron, V; Zhou, X | 1 |
| Bush, JA; Ho, VC; Li, G | 1 |
| Chatterjee, D; Han, Z; Pantazis, P; Wyche, J | 1 |
| Boven, E; Hausheer, FH; Pinedo, HM; Schlüper, HM; Van Hattum, AH | 1 |
| Amodei, S; Benassi, B; Biroccio, A; Del Bufalo, D; Gabellini, C; Zupi, G | 1 |
| Bastow, KF; Cheng, HH; Ito, J; Lee, KH; Luo, TY; Nakanishi, Y; Tachibana, Y; Wang, HK; Xu, Z | 1 |
| McNamee, JP; Ng, CE; Owen, DG; Raaphorst, GP | 1 |
| Ng, CE; Quto b, SS | 1 |
| Bedikian, AY; Ellerhorst, JA; Eton, O; Papadopoulos, NE; Plager, C; Smith, TM | 1 |
| Densmore, CL; Gautam, A; Gilbert, B; Knight, V; Koshkina, N; Melton, S; Roberts, L; Waldrep, JC | 1 |
| Cheung, KJ; Li, G | 1 |
| Brozek, J; Cichorek, M; Kozłowska, K; Witkowski, JM; Zarzeczna, M | 1 |
| Adamson, RH; Mead, JA; Sieber, SM | 1 |
| Boothman, DA; Burrows, HL; Owens, JK; Schea, RA; Strickfaden, S; Wang, M | 1 |
| Giovanella, BC; Hinz, HR; Kozielski, AJ; Mendoza, JT; Pantazis, P; Stehlin, JS; Williams, LJ | 1 |
| Slichenmyer, WJ; Von Hoff, DD | 1 |
| Paparopoli, G; Sciarrino, E | 1 |
4 review(s) available for camptothecin and Melanoma
| Article | Year |
|---|---|
Preclinical and clinical activity of the topoisomerase I inhibitor, karenitecin, in melanoma.
Topics: Animals; Camptothecin; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Drug Evaluation, Preclinical; Humans; Melanoma; Randomized Controlled Trials as Topic; Topoisomerase I Inhibitors | 2011 |
Radiation lethality enhancement with 9-aminocamptothecin: comparison to other topoisomerase I inhibitors.
Topics: Antineoplastic Agents; Camptothecin; Cell Survival; DNA Topoisomerases, Type I; Dose-Response Relationship, Radiation; Humans; Melanoma; Radiation Tolerance; Time Factors; Topoisomerase I Inhibitors; Tumor Cells, Cultured | 1996 |
Pharmacology of antitumor agents from higher plants.
Topics: Animals; Antineoplastic Agents, Phytogenic; Aporphines; Camptothecin; Carcinoma, Squamous Cell; Chemical Phenomena; Chemistry; Etoposide; Humans; Leukemia L1210; Leukemia, Experimental; Leukemia, Lymphoid; Maytansine; Melanoma; Naphthoquinones; Nasopharyngeal Neoplasms; Neoplasms; Neoplasms, Experimental; Phenanthrenes; Structure-Activity Relationship; Teniposide; Vinblastine; Vincristine | 1976 |
New natural products in cancer chemotherapy.
Topics: Adenocarcinoma; Alkaloids; Antineoplastic Agents, Phytogenic; Camptothecin; Carcinoma, Squamous Cell; Chemical Phenomena; Chemistry; Drugs, Investigational; Harringtonines; Homoharringtonine; Humans; Infusions, Intravenous; Irinotecan; Melanoma; Paclitaxel; Phytotherapy; Plant Extracts; Plants, Medicinal; Topotecan | 1990 |
7 trial(s) available for camptothecin and Melanoma
| Article | Year |
|---|---|
Potentiation of a topoisomerase I inhibitor, karenitecin, by the histone deacetylase inhibitor valproic acid in melanoma: translational and phase I/II clinical trial.
Topics: Adult; Aged; Aged, 80 and over; Animals; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cell Line, Tumor; Drug Synergism; Enzyme Inhibitors; Female; Histone Deacetylase Inhibitors; Histones; Humans; Male; Melanoma; Mice; Mice, Nude; Middle Aged; Skin Neoplasms; Topoisomerase I Inhibitors; Valproic Acid | 2009 |
Transarterial chemoembolization with drug-eluting beads preloaded with irinotecan as a first-line approach in uveal melanoma liver metastases: tumor response and predictive value of diffusion-weighted MR imaging in five patients.
Topics: Aged; Antineoplastic Agents; Camptothecin; Chemoembolization, Therapeutic; Chemotherapy, Adjuvant; Delayed-Action Preparations; Diffusion Magnetic Resonance Imaging; Female; Humans; Irinotecan; Liver Neoplasms; Magnetic Resonance Angiography; Male; Melanoma; Microspheres; Middle Aged; Prognosis; Treatment Outcome; Uveal Neoplasms | 2012 |
Combination chemotherapy with docetaxel and irinotecan in metastatic malignant melanoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Docetaxel; Drug Administration Schedule; Female; Humans; Infusions, Intravenous; Irinotecan; Male; Melanoma; Middle Aged; Paclitaxel; Skin Neoplasms; Survival Analysis; Taxoids; Treatment Outcome | 2003 |
Phase II trial of karenitecin in patients with malignant melanoma: clinical and translational study.
Topics: Adult; Aged; Anemia; Camptothecin; DNA Topoisomerases, Type I; DNA Topoisomerases, Type II; Fatigue; Female; HL-60 Cells; Humans; Male; Melanoma; Middle Aged; Nausea; Neutropenia; Survival Analysis; Thrombocytopenia; Treatment Outcome; Vomiting | 2005 |
Analysis of topoisomerase I/DNA complexes in patients administered topotecan.
Topics: Antineoplastic Agents; Camptothecin; DNA Damage; DNA Topoisomerases, Type I; DNA, Neoplasm; HeLa Cells; Humans; Lymphoma, Non-Hodgkin; Melanoma; Topotecan | 1995 |
Phase II trial of topotecan in malignant melanoma.
Topics: Adult; Aged; Antineoplastic Agents; Camptothecin; Enzyme Inhibitors; Female; Humans; Male; Melanoma; Middle Aged; Neoplasm Recurrence, Local; Topotecan | 1997 |
Phase II trial of 9-nitrocamptothecin (RFS 2000) for patients with metastatic cutaneous or uveal melanoma.
Topics: Adult; Aged; Antineoplastic Agents; Camptothecin; Diarrhea; Female; Humans; Male; Melanoma; Middle Aged; Neoplasm Metastasis; Neutropenia; Skin Neoplasms; Treatment Outcome; Uveal Neoplasms | 2002 |
49 other study(ies) available for camptothecin and Melanoma
| Article | Year |
|---|---|
Prodrug analogues of the antitumor alkaloid camptothecin.
Topics: Animals; Antineoplastic Agents; Camptothecin; Leukemia L1210; Leukemia, Experimental; Lung Neoplasms; Melanoma; Mice; Neoplasms, Experimental | 1979 |
Small molecule obatoclax (GX15-070) antagonizes MCL-1 and overcomes MCL-1-mediated resistance to apoptosis.
Topics: Animals; Antineoplastic Agents; Apoptosis; bcl-2 Homologous Antagonist-Killer Protein; Boronic Acids; Bortezomib; Cell Line, Tumor; Cysteine Proteinase Inhibitors; Drug Resistance, Neoplasm; Humans; Indoles; Melanoma; Mice; Mitochondria; Myeloid Cell Leukemia Sequence 1 Protein; Neoplasm Proteins; Proteasome Inhibitors; Proto-Oncogene Proteins c-bcl-2; Pyrazines; Pyrroles | 2007 |
Discovery of potent molecular chimera (CM358) to treat human metastatic melanoma.
Topics: Animals; Antineoplastic Agents; Cell Proliferation; DNA Topoisomerases, Type II; Dose-Response Relationship, Drug; Drug Discovery; Drug Screening Assays, Antitumor; Heterocyclic Compounds, 3-Ring; Humans; Melanoma; Mice; Mice, Nude; Models, Molecular; Molecular Structure; Neoplasms, Experimental; Pyrimidinones; Structure-Activity Relationship; Topoisomerase II Inhibitors | 2017 |
In Silico Molecular Docking Approach of Melanin Against Melanoma Causing MITF Proteins and Anticancer, Oxidation-Reduction, Photoprotection, and Drug-Binding Affinity Properties of Extracted Melanin from Streptomyces sp. strain MR28.
Topics: Camptothecin; Cell Line, Tumor; Doxorubicin; Humans; Melanins; Melanoma; Microphthalmia-Associated Transcription Factor; Molecular Docking Simulation; Oxidation-Reduction; Streptomyces | 2023 |
RJT-101, a novel camptothecin derivative, is highly effective in the treatment of melanoma through DNA damage by targeting topoisomerase 1.
Topics: Animals; Antineoplastic Agents; Camptothecin; Cell Line; Cell Line, Tumor; Cell Proliferation; DNA Damage; DNA Topoisomerases, Type I; Drug Resistance, Neoplasm; Female; Humans; Melanoma; Mice, Inbred C57BL; Mice, Nude; Molecular Structure; Skin Neoplasms; Topoisomerase I Inhibitors; Tumor Burden; Xenograft Model Antitumor Assays | 2020 |
A dermatan sulfate-functionalized biomimetic nanocarrier for melanoma targeted chemotherapy.
Topics: Animals; Antineoplastic Agents, Phytogenic; Apoptosis; Biomimetic Materials; Camptothecin; Cell Proliferation; Dermatan Sulfate; Drug Carriers; Drug Liberation; Drug Screening Assays, Antitumor; Melanoma; Mice; Molecular Structure; Nanoparticles; Particle Size; Skin Neoplasms; Surface Properties; Tumor Cells, Cultured | 2020 |
HMGB1 modulates the balance between senescence and apoptosis in response to genotoxic stress.
Topics: Animals; Apoptosis; Camptothecin; Cell Line, Tumor; Cells, Cultured; Cellular Senescence; Colonic Neoplasms; Cyclin-Dependent Kinase Inhibitor p21; DNA Damage; Doxorubicin; Fibroblasts; HMGB1 Protein; Humans; Melanoma; Mice | 2019 |
A retrospective analysis of 141 patients with liver metastases from uveal melanoma: a two-cohort study comparing transarterial chemoembolization with CPT-11 charged microbeads and historical treatments.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Camptothecin; Chemoembolization, Therapeutic; Databases, Factual; Feasibility Studies; Female; Humans; Irinotecan; Kaplan-Meier Estimate; Liver Neoplasms; Male; Melanoma; Middle Aged; Proportional Hazards Models; Retrospective Studies; Risk Factors; Treatment Outcome; Uveal Neoplasms; Young Adult | 2015 |
Transarterial Chemoembolization of Liver Metastases from Uveal Melanoma Using Irinotecan-Loaded Beads: Treatment Response and Complications.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Phytogenic; Camptothecin; Chemoembolization, Therapeutic; Contrast Media; Drug Delivery Systems; Female; Humans; Irinotecan; Liver; Liver Neoplasms; Male; Melanoma; Middle Aged; Radiographic Image Enhancement; Retrospective Studies; Therapeutics; Tomography, X-Ray Computed; Uveal Neoplasms; Young Adult | 2015 |
The reduction of oxidative stress by nanocomposite Fullerol decreases mucositis severity and reverts leukopenia induced by Irinotecan.
Topics: Animals; Antineoplastic Agents, Phytogenic; Camptothecin; Fullerenes; Glutathione; Ileum; Interleukin-1beta; Intestinal Mucosa; Irinotecan; Leukopenia; Male; Melanoma; Mice, Inbred C57BL; Mice, Transgenic; Mucositis; Nanocomposites; Oxidative Stress; Peroxidase; Thiobarbituric Acid Reactive Substances; Tumor Burden | 2016 |
Establishment of a dog model for the p53 family pathway and identification of a novel isoform of p21 cyclin-dependent kinase inhibitor.
Topics: Amino Acid Sequence; Animals; Antineoplastic Agents; Bone Neoplasms; Camptothecin; Cell Line; Cell Line, Tumor; Conserved Sequence; Cyclin-Dependent Kinase Inhibitor p21; DNA Damage; Dogs; Doxorubicin; Humans; Kidney; Melanoma; Mice; Models, Animal; Molecular Sequence Data; Osteosarcoma; Sequence Alignment; Sequence Homology, Amino Acid; Tumor Suppressor Protein p53 | 2009 |
Antimetastatic activity of MONCPT in preclinical melanoma mice model.
Topics: Animals; Camptothecin; Cell Adhesion; Cell Hypoxia; Cell Line, Tumor; Cell Movement; Cell Proliferation; Cell Separation; Disease Models, Animal; Drug Screening Assays, Antitumor; Extracellular Signal-Regulated MAP Kinases; Female; Green Fluorescent Proteins; Hypoxia-Inducible Factor 1, alpha Subunit; Lung Neoplasms; Melanoma; Mice; Mice, Inbred C57BL; Neoplasm Invasiveness; Neoplasm Metastasis; Phosphorylation; Proto-Oncogene Proteins c-akt; Signal Transduction; Transduction, Genetic; Vascular Endothelial Growth Factor A | 2010 |
NF-kappaB inhibition through proteasome inhibition or IKKbeta blockade increases the susceptibility of melanoma cells to cytostatic treatment through distinct pathways.
Topics: Animals; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Boronic Acids; Bortezomib; Camptothecin; Cell Line, Tumor; Drug Resistance, Neoplasm; Drug Synergism; Gene Expression Regulation, Neoplastic; Humans; I-kappa B Kinase; Lung Neoplasms; Melanoma; Mice; NF-kappa B; Oxazines; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Protein Kinase Inhibitors; Pyrazines; Pyridines; Skin Neoplasms | 2010 |
Therapeutic targeting of melanoma cells using neural stem cells expressing carboxylesterase, a CPT-11 activating enzyme.
Topics: Animals; Antineoplastic Agents, Phytogenic; Camptothecin; Carboxylesterase; Cell Line, Tumor; Cell Movement; Cytokines; Enzyme Inhibitors; Humans; Irinotecan; Melanoma; Neurons; Rabbits; Stem Cells | 2010 |
Dual inhibition of topoisomerases enhances apoptosis in melanoma cells.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Camptothecin; Caspases; Cell Proliferation; DNA Topoisomerases, Type I; DNA Topoisomerases, Type II; Etoposide; Humans; Immunoblotting; JNK Mitogen-Activated Protein Kinases; MAP Kinase Signaling System; Melanoma; Membrane Potential, Mitochondrial; Mutation; Oxidative Stress; Topoisomerase I Inhibitors; Topoisomerase II Inhibitors; Tumor Cells, Cultured; Tumor Suppressor Protein p53 | 2010 |
Evolution of laparoscopic left lateral sectionectomy without the Pringle maneuver: through resection of benign and malignant tumors to living liver donation.
Topics: Adenocarcinoma; Adenoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Blood Loss, Surgical; Camptothecin; Carcinoma, Hepatocellular; Combined Modality Therapy; Disease-Free Survival; Female; Fluorouracil; Follow-Up Studies; Gastrointestinal Stromal Tumors; Hepatectomy; Humans; Laparoscopy; Length of Stay; Leucovorin; Liver Neoplasms; Liver Transplantation; Living Donors; Male; Melanoma; Middle Aged; Organoplatinum Compounds; Postoperative Complications; Retrospective Studies; Tissue and Organ Harvesting | 2011 |
Camptothecin-induced death of amelanotic and melanotic melanoma cells in different phases of cell cycle.
Topics: Animals; Antineoplastic Agents, Phytogenic; Apoptosis; Camptothecin; Cell Cycle; Cricetinae; Male; Melanoma; Melanoma, Amelanotic; Mesocricetus; Skin Neoplasms | 2011 |
A self-contained enzyme activating prodrug cytotherapy for preclinical melanoma.
Topics: Animals; Antineoplastic Agents, Phytogenic; Camptothecin; Carboxylesterase; Cell Transplantation; DNA Primers; Drug Carriers; Drug Evaluation, Preclinical; Female; Genes, Transgenic, Suicide; Irinotecan; Lung Neoplasms; Magnetics; Melanoma; Mice; Mice, Inbred C57BL; Monocyte-Macrophage Precursor Cells; Nanoparticles; Prodrugs | 2012 |
Camptothecin induces p53-dependent and -independent apoptogenic signaling in melanoma cells.
Topics: Antineoplastic Agents, Phytogenic; Apoptosis; Camptothecin; Caspase 2; Cell Line, Tumor; Cysteine Endopeptidases; DNA Damage; DNA-Binding Proteins; Humans; Melanoma; MicroRNAs; Mitochondria; Nuclear Proteins; Proto-Oncogene Proteins c-bcl-2; Real-Time Polymerase Chain Reaction; Signal Transduction; Topoisomerase I Inhibitors; Tumor Protein p73; Tumor Suppressor Protein p53; Tumor Suppressor Proteins | 2011 |
Cisplatin down-regulation of cellular Fas-associated death domain-like interleukin-1beta-converting enzyme-like inhibitory proteins to restore tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis in human melanoma cells.
Topics: Antineoplastic Agents; Apoptosis; Apoptosis Regulatory Proteins; Camptothecin; Caspases; Cell Line, Tumor; Cisplatin; Etoposide; Flow Cytometry; Humans; Melanoma; Membrane Glycoproteins; TNF-Related Apoptosis-Inducing Ligand; Tumor Necrosis Factor-alpha | 2003 |
Apoptosis protease activator protein-1 expression is dispensable for response of human melanoma cells to distinct proapoptotic agents.
Topics: Amidines; Antineoplastic Agents; Apoptosis; Apoptotic Protease-Activating Factor 1; Benzylamines; Camptothecin; Caspase 9; Caspase Inhibitors; Caspases; Celecoxib; Cell Line, Tumor; Enzyme Activation; Enzyme Inhibitors; Humans; Immunohistochemistry; Melanoma; Protein Biosynthesis; Proteins; Pyrazoles; RNA, Messenger; Sulfonamides | 2004 |
Efficacy of the novel camptothecin gimatecan against orthotopic and metastatic human tumor xenograft models.
Topics: Animals; Brain; Camptothecin; Female; Humans; Melanoma; Mice; Mice, Nude; Neoplasm Metastasis; Neoplasm Transplantation; Neoplasms, Experimental; Nervous System Neoplasms; Ovarian Neoplasms; Time Factors; Xenograft Model Antitumor Assays | 2004 |
Enhanced antitumour efficacy of gimatecan in combination with Bcl-2 antisense oligonucleotide in human melanoma xenografts.
Topics: Administration, Oral; Animals; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cell Division; Cell Line, Tumor; Cell Survival; Drug Resistance, Neoplasm; Female; Humans; Melanoma; Mice; Mice, Nude; Neoplasm Transplantation; Proto-Oncogene Proteins c-bcl-2; Thionucleotides; Transplantation, Heterologous | 2005 |
Expression of drug pathway proteins is independent of tumour type.
Topics: Adenocarcinoma; Antineoplastic Agents, Phytogenic; Brain Neoplasms; Breast Neoplasms; Camptothecin; Colonic Neoplasms; Cytochrome P-450 Enzyme System; Drug Resistance, Neoplasm; Enzyme Inhibitors; Female; Humans; Immunohistochemistry; Irinotecan; Lung Neoplasms; Lymphoma; Male; Melanoma; Multidrug Resistance-Associated Protein 2; Multidrug Resistance-Associated Proteins; Neoplasm Proteins; Neoplasms; Ovarian Neoplasms; Prostatic Neoplasms; Tissue Array Analysis | 2006 |
Evaluation of antimetastatic activity and systemic toxicity of camptothecin-loaded microspheres in mice injected with B16-F10 melanoma cells.
Topics: Animals; Antineoplastic Agents, Phytogenic; Camptothecin; Capsules; Delayed-Action Preparations; Disease Models, Animal; Drug Carriers; Drug Delivery Systems; Melanoma; Mice; Microspheres; Neoplasm Metastasis; Neoplasm Transplantation; Particle Size | 2006 |
Mitochondrial transmembrane potential in spontaneous and camptothecin-induced apoptosis of melanotic and amelanotic melanoma cells.
Topics: Animals; Antineoplastic Agents, Phytogenic; Apoptosis; Blotting, Western; Camptothecin; Cricetinae; Cytochromes c; Cytosol; Flow Cytometry; Male; Melanoma; Membrane Potential, Mitochondrial; Mesocricetus; Poly(ADP-ribose) Polymerases; Time Factors; Tumor Cells, Cultured | 2007 |
Plasma, tumor, and tissue disposition of STEALTH liposomal CKD-602 (S-CKD602) and nonliposomal CKD-602 in mice bearing A375 human melanoma xenografts.
Topics: Animals; Camptothecin; Cell Line, Tumor; Drug Screening Assays, Antitumor; Extracellular Fluid; Female; Humans; Liposomes; Melanoma; Mice; Mice, SCID; Microdialysis; Polyethylene Glycols; Tissue Distribution; Transplantation, Heterologous; Xenograft Model Antitumor Assays | 2007 |
Genomic analyses identify gene candidates for acquired irinotecan resistance in melanoma cells.
Topics: Antineoplastic Agents, Phytogenic; Biomarkers, Tumor; Camptothecin; Chromosomes, Human, Pair 14; Drug Resistance, Neoplasm; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Humans; Irinotecan; Melanoma; Nucleic Acid Hybridization; Oligonucleotide Array Sequence Analysis; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Tumor Cells, Cultured | 2008 |
Growth inhibition of human cancer metastases by camptothecins in newly developed xenograft models.
Topics: Adenocarcinoma; Adrenal Gland Neoplasms; Animals; Antineoplastic Agents, Phytogenic; Brain Neoplasms; Burkitt Lymphoma; Camptothecin; Carcinoma, Squamous Cell; Drug Screening Assays, Antitumor; Humans; Liver Neoplasms; Male; Melanoma; Mice; Mice, Inbred Strains; Mice, Nude; Reproducibility of Results; Tumor Cells, Cultured | 1995 |
Inhibition of potentially lethal and sublethal damage repair by camptothecin and etoposide in human melanoma cell lines.
Topics: Camptothecin; Cell Death; DNA; DNA Repair; DNA Topoisomerases, Type I; DNA Topoisomerases, Type II; Etoposide; Humans; Melanoma; Radiation Tolerance; Radiation-Sensitizing Agents; Topoisomerase I Inhibitors; Topoisomerase II Inhibitors; Tumor Cells, Cultured | 1994 |
Therapeutic efficacy of camptothecin derivatives against human malignant melanoma xenografts.
Topics: Animals; Antineoplastic Agents; Camptothecin; Drug Administration Routes; Drug Screening Assays, Antitumor; Humans; Melanoma; Mice; Mice, Nude; Neoplasm Transplantation; Transplantation, Heterologous | 1994 |
Cytotoxic efficacy of 9-nitrocamptothecin in the treatment of human malignant melanoma cells in vitro.
Topics: Animals; Antineoplastic Agents; Camptothecin; Cell Cycle; Cell Division; Drug Administration Schedule; Humans; Kinetics; Melanocytes; Melanoma; Mice; Mice, Nude; Tumor Cells, Cultured | 1994 |
Modulation of melphalan cytotoxic activity in human melanoma cell lines.
Topics: Antineoplastic Agents, Alkylating; Blotting, Northern; Camptothecin; Drug Interactions; Enzyme Inhibitors; Ethacrynic Acid; Humans; Melanoma; Melphalan; Temperature; Topoisomerase I Inhibitors; Topotecan; Tumor Cells, Cultured | 1996 |
Concentration and timing dependence of lethality enhancement between topotecan, a topoisomerase I inhibitor, and ionizing radiation.
Topics: Antineoplastic Agents; Camptothecin; Cell Survival; Combined Modality Therapy; Fibroblasts; Humans; Melanoma; Neoplasms; Radiation Dosage; Radiation Tolerance; Time Factors; Topoisomerase I Inhibitors; Topotecan; Tumor Cells, Cultured | 1996 |
Antitumor activity of a novel quinoline derivative, TAS-103, with inhibitory effects on topoisomerases I and II.
Topics: Adenocarcinoma; Aminoquinolines; Animals; Antineoplastic Agents; Camptothecin; Cisplatin; Colonic Neoplasms; DNA; DNA Topoisomerases, Type I; DNA Topoisomerases, Type II; Dose-Response Relationship, Drug; Etoposide; Humans; Indenes; Indoles; Irinotecan; Lung Neoplasms; Male; Melanoma; Mice; Mice, Inbred Strains; Neoplasm Transplantation; Neoplasms, Experimental; Pyridines; Topoisomerase I Inhibitors; Topoisomerase II Inhibitors; Tumor Cells, Cultured | 1997 |
Chemotherapy-induced apoptosis in melanoma cells is p53 dependent.
Topics: Antineoplastic Agents; Apoptosis; Camptothecin; Cell Division; Cell Survival; Cisplatin; DNA Fragmentation; DNA, Neoplasm; Electrophoresis, Agar Gel; Genes, p53; Humans; Melanocytes; Melanoma; Mutation; Skin Neoplasms; Tumor Cells, Cultured; Vincristine | 1998 |
p53-dependent apoptosis in melanoma cells after treatment with camptothecin.
Topics: Animals; Antineoplastic Agents, Phytogenic; Apoptosis; ATP Binding Cassette Transporter, Subfamily B, Member 1; bcl-2 Homologous Antagonist-Killer Protein; bcl-2-Associated X Protein; Camptothecin; Cricetinae; Cyclin-Dependent Kinase Inhibitor p21; Cyclins; Gene Expression; Genes, p53; Humans; Melanoma; Membrane Proteins; Mutation; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-bcl-2; Tumor Cells, Cultured | 2000 |
Differentiation of human malignant melanoma cells that escape apoptosis after treatment with 9-nitrocamptothecin in vitro.
Topics: Animals; Antineoplastic Agents; Apoptosis; Camptothecin; Cell Differentiation; Cyclin-Dependent Kinase Inhibitor p16; Cyclin-Dependent Kinase Inhibitor p21; Cyclins; Flow Cytometry; G2 Phase; Humans; Melanins; Melanoma; Mice; Mice, Nude; Tumor Cells, Cultured | 1999 |
New highly lipophilic camptothecin BNP1350 is an effective drug in experimental human cancer.
Topics: Animals; Antineoplastic Agents, Phytogenic; ATP Binding Cassette Transporter, Subfamily B, Member 1; Camptothecin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Small Cell; Colonic Neoplasms; Doxorubicin; Drug Resistance, Multiple; Enzyme Inhibitors; Female; Humans; Irinotecan; Lung Neoplasms; Melanoma; Mice; Mice, Nude; Neoplasms; Ovarian Neoplasms; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2000 |
c-Myc down-regulation increases susceptibility to cisplatin through reactive oxygen species-mediated apoptosis in M14 human melanoma cells.
Topics: Antineoplastic Agents; Apoptosis; bcl-2-Associated X Protein; bcl-X Protein; Camptothecin; Caspase 1; Caspase 3; Caspases; Cisplatin; Down-Regulation; Doxorubicin; Enzyme Activation; Humans; Melanoma; Peptide Hydrolases; Poly (ADP-Ribose) Polymerase-1; Poly(ADP-ribose) Polymerases; Proteins; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-bcl-2; Proto-Oncogene Proteins c-myc; Reactive Oxygen Species; Tumor Cells, Cultured; Tumor Suppressor Protein p53 | 2001 |
Cytotoxic pheophorbide-related compounds from Clerodendrum calamitosum and C. cyrtophyllum.
Topics: Adenocarcinoma; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Camptothecin; Cell Survival; Chlorophyll; Dose-Response Relationship, Drug; Drug Resistance; Etoposide; Female; Humans; Ileal Neoplasms; KB Cells; Kidney Neoplasms; Lung Neoplasms; Magnetic Resonance Spectroscopy; Melanoma; Molecular Structure; Ovarian Neoplasms; Plant Leaves; Plant Stems; Plants, Medicinal; Stereoisomerism; Structure-Activity Relationship; Taiwan; Tumor Cells, Cultured; Vincristine | 2001 |
Potentiation of cell killing by low-dose-rate radiation by camptothecin is related to an increase in the level of DNA double-strand breaks.
Topics: Camptothecin; Cell Survival; Comet Assay; DNA; DNA Damage; DNA, Neoplasm; Dose-Response Relationship, Radiation; Gamma Rays; Humans; Melanoma; Radiation Tolerance; Radiation-Sensitizing Agents; Tumor Cells, Cultured; Tumor Stem Cell Assay | 2002 |
Comparison of apoptotic, necrotic and clonogenic cell death and inhibition of cell growth following camptothecin and X-radiation treatment in a human melanoma and a human fibroblast cell line.
Topics: Antineoplastic Agents, Phytogenic; Apoptosis; Camptothecin; Cell Death; Combined Modality Therapy; Fibroblasts; Humans; Melanoma; Necrosis; Stem Cells; Tumor Cells, Cultured; X-Rays | 2002 |
Growth inhibition of established B16-F10 lung metastases by sequential aerosol delivery of p53 gene and 9-nitrocamptothecin.
Topics: Aerosols; Animals; Antineoplastic Agents; Camptothecin; Combined Modality Therapy; Genes, p53; Genetic Therapy; Liposomes; Lung Neoplasms; Melanoma; Mice; Mice, Inbred C57BL; Neoplasms, Experimental; Survival Rate | 2002 |
The tumour suppressor p33ING1 does not enhance camptothecin-induced cell death in melanoma cells.
Topics: Antineoplastic Agents, Phytogenic; Camptothecin; Cell Cycle Proteins; Cell Death; DNA-Binding Proteins; Genes, Tumor Suppressor; Humans; Inhibitor of Growth Protein 1; Intracellular Signaling Peptides and Proteins; Melanoma; Nuclear Proteins; Proteins; Tumor Cells, Cultured; Tumor Suppressor Protein p53; Tumor Suppressor Proteins | 2002 |
Heterogeneous susceptibility to spontaneous and induced apoptosis characterizes two related transplantable melanomas with different biological properties.
Topics: Animals; Annexin A5; Antineoplastic Agents, Phytogenic; Apoptosis; Camptothecin; Caspase 3; Caspases; Cells, Cultured; Cricetinae; DNA Fragmentation; Enzyme Inhibitors; Flow Cytometry; Humans; Jurkat Cells; Male; Melanoma; Mesocricetus; Tumor Cells, Cultured | 2002 |
Posttreatment exposure to camptothecin enhances the lethal effects of x-rays on radioresistant human malignant melanoma cells.
Topics: Camptothecin; Cell Survival; DNA; Humans; Melanoma; Radiation-Sensitizing Agents; Topoisomerase I Inhibitors; Topoisomerase II Inhibitors; Tumor Cells, Cultured; X-Rays | 1992 |
Complete inhibition of growth followed by death of human malignant melanoma cells in vitro and regression of human melanoma xenografts in immunodeficient mice induced by camptothecins.
Topics: Animals; Body Weight; Camptothecin; Cell Death; Cell Division; Drug Screening Assays, Antitumor; Graft Survival; Male; Melanoma; Mice; Mice, Nude; Neoplasm Transplantation; Remission Induction; Tumor Cells, Cultured | 1992 |
[Recent diagnostic and therapeutic acquisitions in malignant melanoma].
Topics: Antineoplastic Agents; Camptothecin; Chloroquine; Colchicine; Humans; Hydroxyurea; Imidazoles; Immunotherapy; Iodine Radioisotopes; Melanoma; Nitrosourea Compounds; Radionuclide Imaging; Triazenes | 1974 |